-
Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
15 Oct 2025 22:15 GMT
… with multikinase inhibitors, such as sorafenib and lenvatinib, and are … the efficacy of immunotherapy on lung cancer, head and neck cancer, … ) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment … L1-positive non-small-cell lung cancer. N Engl J Med. …
-
Chemoradiotherapy with or Without Anlotinib for Postoperative Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma: A Real-World Observational Study
15 Oct 2025 22:15 GMT
… carcinoma, non-small cell lung cancer (NSCLC), and ESCC.8 … transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE … extensive-stage small-cell lung cancer after second-line or … association for the study of lung cancer (IASLC) lymph node map …
-
The Role of SLC7A11 in Tumor Progression and the Regulation Mechanisms Involved in Ferroptosis
14 Oct 2025 14:18 GMT
… in non-small cell lung cancer cells via regulating … LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in … promotes non-small cell lung cancer through SLC7A11-mediated-ferroptosis. … drives non-small cell lung cancer growth by sequestering miR …
-
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types
13 Oct 2025 13:40 GMT
… positive) non-small cell lung cancer (NSCLC). OPDIVO® (nivolumab … been previously treated with sorafenib. This indication is … metastatic non-small cell lung cancer, in combination with … cell lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
16 May 2025 11:14 GMT
… pCR and MPR.
About Lung Cancer
Lung cancer is the leading cause … been previously treated with sorafenib.
OPDIVO® (nivolumab) … metastatic non-small cell lung cancer, in combination with … cell lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity
17 Jul 2025 18:58 GMT
… without any further purification. Sorafenib (Ark Pharma Scientific, … -mediated ASGPR targeting. Sorafenib, released from hepatocytes, … Phosphate buffer solution; Sor, Sorafenib; STING, Stimulator of … gefitinib resistance in lung cancer by activating ERBB3 …
-
Camrelizumab Combo Doubles 5-Year Survival in Phase 3 Lung Cancer Trial
02 Apr 2025 23:47 GMT
… patients with advanced squamous lung cancer, according to a press … at the 2025 European Lung Cancer Congress (ELCC). The trial … Center consistently shows that lung cancer has the highest incidence … 15.2 months with sorafenib. Median progression-free survival …
-
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
28 Mar 2025 13:11 GMT
… of four tumor types: lung cancer, bladder cancer, esophageal … pathologic response.
About Lung Cancer
Lung cancer is the leading cause … been previously treated with sorafenib. This indication is … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Emerging Plant-Derived Exosome-Like Particles Reveal Key Therapeutic Benefits. A Comprehensive Review of Evidence
11 Oct 2025 15:41 GMT
… B for Non-Small Cell Lung Cancer Therapy[J]. Int J Nanomed … vesicles for oral delivery of sorafenib[J]. Eur J Pharm Sci …
-
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
19 Feb 2025 12:09 GMT
… positive) non-small cell lung cancer (NSCLC).
OPDIVO® (nivolumab … been previously treated with sorafenib. This indication is … metastatic non-small cell lung cancer, in combination with … cell lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
About
© 1995-2025